0.000USD0.000Pre-market 07/27, 09:30 (ET)
3.99MMarket Cap
LossP/E TTM
Key Figures
2.810Open
2.880High
56.72KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.73%Turnover Ratio
2.880Prev. Close
2.415Low
68.92KTurnover
LossP/E Static
2.97P/B
0.00%Div Yield TTM
-8.54%ROA
8.74652wk High
0.69Volume Ratio
-30.02MNet Profit
3.28MShares
-8.2976EPS TTM
2.07Beta
-27725.80%ROE
0.25052wk Low
16.15%Amplitude
99.83%Gross Margin
3.99MMarket Cap
15.65Reward/Risk
11.47%Risk Rate
Currency: USD Updated: 2026-07-24 Key Insights
HCW Biologics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HCW Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
HCW Biologics Inc Highlights
StrengthsRisks
HCW Biologics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
HCW Biologics Inc Info
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Ticker SymbolHCWB
CompanyHCW Biologics Inc
CEOWong (Hing C)
Websitehttps://hcwbiologics.com/
Shareholders
FAQs
What is the current price of HCW Biologics Inc (HCWB)?
The current price of HCW Biologics Inc (HCWB) is 2.50.
What is the symbol of HCW Biologics Inc?
The ticker symbol of HCW Biologics Inc is HCWB.
What is the 52-week high of HCW Biologics Inc?
The 52-week high of HCW Biologics Inc is 8.75.
What is the 52-week low of HCW Biologics Inc?
The 52-week low of HCW Biologics Inc is 0.25.
What is the market capitalization of HCW Biologics Inc?
The market capitalization of HCW Biologics Inc is 3.99M.
Is HCW Biologics Inc (HCWB) currently rated as Buy, Hold, or Sell?
According to analysts, HCW Biologics Inc (HCWB) has an overall rating of Buy, with a price target of 30.00.
What is the Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB)?
The Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB) is -63.78.
